Decreased glucose tolerance

In an attempt to conserve sodium, the kidney secretes renin increased plasma renin activity increases the release of aldosterone, which regulates the absorption of potassium and leads to kafluresis and hypokalemia. Hypokalemia is responsible in part for decreased glucose intolerance (82). Hyponatremia, postural hypotension, and pre-renal azotemia are considered of tittle consequence. Hypemricemia and hypercalcemia are not unusual, but are not considered harmful. However, hypokalemia, progressive decreased glucose tolerance, and increased semm cholesterol [57-88-5] levels are considered... 

Decrease baroreflex sensitivity Decrease -receptor response Decrease 2 -receptor response Increase sensitivity to barbiturates Decrease glucose tolerance... 

The incidence of diabetes and decreased glucose tolerance among the elderly is well documented [116,135-137]. Because of this, formulators should make every attempt to avoid using any sugar-containing excipients in their production processes. 

Diabetes Observe diabetic or borderline diabetic patients closely for decreased glucose tolerance. Avoid doses greater than 3 g/day. 

Lab test abnormalities Abnormalities of hepatic function tests, decreased glucose tolerance, gout, hyperuricemia. 

M/sce/Zaneoas. Atrial fibrillation and other cardiac arrhythmias, cystoid macular edema, decreased glucose tolerance, hypotension, orthostasis, toxic amblyopia, transient headache. 

Transient side effects, gastrointestinal discomfort and decreased glucose tolerance, usually last only a few weeks after initiation of therapy. The most signihcant... 

Diabetic patients may note decreased glucose tolerance... 

Lithium blocks the release of thyroxine (T4) and triiodothyronine (T3) mediated by thyrotropin (Kleiner et ah, 1999). This results in a decrease in circulating T4 and T3 concentrations and a feedback increase in serum thyrotropin concentration. It also inhibits thyrotropin-stimulated adenylate cyclase activity (Kleiner et ah, 1999). Lithium has varying effects on carbohydrate metabolism. Increased and decreased glucose tolerance and decreased sensitivity to insulin have been observed (Van derVelde Gordon, 1969). In animals, lithium decreases hepatic cholesterol and fatty acid synthesis. 

Decreased glucose tolerance occurs, perhaps due to a peripheral effect reducing the action of insulin. 

It acts as a cofactor for glycogen phosphorylase in glycogenolysis. Decreased glucose tolerance may be associated with vitamin B-6 deficiency. 

Mild gynecomastia increased frequency of vascular accidents myelosuppression (uncommon) edema dyspnea pulmonary infiltrates and fibrosis decreased glucose tolerance thrombosis hypertension... 

Endocrine Effects. Autopsy of a woman who died after taking 1.03 mg 2,4-DNP for 46 days revealed extensive vascularization of the spleen and pituitary accompanied by goiter in the thyroid (Goldman and Haber 1936). Decreased glucose tolerance was seen in one clinical study in 5 of 8 patients after 1 -2 weeks of treatment and in 4 of 4 after 3-4 weeks of treatment with 4.3 mg/kg/day 2,4-DNP (MacBryde and Taussig 1935). An additional finding in humans given 2,4-DNP for short durations... 

Women with diabetes are at increased risk of heart disease and stroke, particularly if the woman smokes. Estrogens and progestins may slightly decrease glucose tolerance, but this is unlikely to happen with low-dose OCs. 

Long-term use of thiazide diuretics also may result in decreased glucose tolerance and increased blood lipid ( total triglyceride) content. 

The clinical use of low-dose progestagens produced few reported severe side-effects. Women with subcutaneously implanted silastic capsules containing MA have had few side-effects and no gross evidence of total tissue reaction from the silastic.Norgestrel, at a dally dose of 50 pg, did not decrease glucose tolerance or raise serum transaminase levels. 6... 

The longitudinal, postmarketing, observational PATRO children study (N = 1837, mean age = 9.33 years, 56.9% male) found that adverse events associated with Omnitrope with an incidence rate >0.001 (based on 2851.16 patient years) were headache, hypothyroidism, arthralgia, pain in extremity, injection-site haematoma, decreased glucose tolerance, asthenia, injection-site pain, increased blood creatine, phosphokinase and myalgia [36 -]. There were no confirmed cases of diabetes (type 1 or 2) or malignancy related to treatment and no anti-hGH antibodies have been found in a subset of 30 patients. 

---